AbTCR-CSR therapeutic trial in an OCI-AML-2 human AML animal model. OCI-AML-2 cells (0.5 million) were injected IV into NSG mice. Groups were blindly assigned to treatment groups. (A) Mock T cells, CSR-only cells, or ESK2 AbTCR-CSR cells (1 million) were injected IV on day 4 and day 12 after tumor cell injection. (B) Tumor burden was assessed by BLI on the indicated days. (C) Mean tumor burden was calculated by summing the luminescent signal of each mouse, and the average signal for each group (n = 4 per group) was plotted. (D) Survival of mice from experimental groups. A comparison of the differences of clone no. 18 or no. 34 vs the 2 control groups was calculated using the Mantel-Cox test; ∗∗∗P < .001. Max, maximum; min, minimum.